OverviewSuggest Edit

Regenx Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The Company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The Company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, Regenxoffers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers.
TypePublic
Founded2009
HQRockville, US
Websiteregenxbio.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Feb 2019)192(+39%)
Job Openings16
Revenue (FY, 2018)$218.5 M(+2003%)
Share Price (May 2019)$43 (+3%)

Key People/Management at Regenxbio

Ken Mills

Ken Mills

President and Chief Executive Officer
Vit Vasista

Vit Vasista

CFO
Stephen Yoo

Stephen Yoo

Chief Medical Officer
Olivier Danos

Olivier Danos

Chief Scientific Officer
Curran Simpson

Curran Simpson

Senior Vice President, Technical Operations
Kimberly Sloan

Kimberly Sloan

Senior Vice President, Human Resources
Show more

Regenxbio Office Locations

Regenxbio has an office in Rockville
Rockville, US (HQ)
9712 Medical Center Dr #100
Show all (1)

Regenxbio Financials and Metrics

Regenxbio Revenue

Regenxbio's revenue was reported to be $218.51 m in FY, 2018
USD

Revenue (Q1, 2019)

884.0k

Gross profit (Q1, 2019)

855.0k

Gross profit margin (Q1, 2019), %

96.7%

Net income (Q1, 2019)

(32.2m)

EBIT (Q1, 2019)

(35.9m)

Market capitalization (21-May-2019)

1.6b

Closing stock price (21-May-2019)

43.0

Cash (31-Mar-2019)

55.9m
Regenxbio's current market capitalization is $1.6 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

7.6m4.6m10.4m218.5m

Cost of goods sold

9.6m

Gross profit

208.9m

Gross profit Margin, %

96%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

1.1m393.0k2.4m125.0k455.0k6.6m1.3m132.4m40.0m5.3m884.0k

Cost of goods sold

3.9m517.0k29.0k

Gross profit

36.2m4.8m855.0k

Gross profit Margin, %

90%90%97%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

54.1m24.8m46.7m75.6m

Accounts Receivable

1.0m473.0k8.6m

Current Assets

118.1m93.4m168.0m337.9m

PP&E

538.0k9.3m14.0m28.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(22.8m)(63.0m)(73.2m)99.9m

Depreciation and Amortization

80.0k544.0k2.7m4.0m

Accounts Payable

590.0k186.0k2.6m(218.0k)

Cash From Operating Activities

(22.5m)(48.6m)(58.0m)104.6m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(17.6m)(10.8m)(25.2m)(43.4m)(22.0m)(36.5m)(57.2m)104.2m114.8m95.6m(32.2m)

Depreciation and Amortization

43.0k48.0k104.0k264.0k554.0k1.3m2.0m834.0k1.7m2.7m1.6m

Accounts Payable

317.0k(182.0k)930.0k3.6m2.5m2.7m1.1m477.0k(340.0k)156.0k316.0k

Cash From Operating Activities

(18.1m)(7.9m)(16.3m)(28.1m)(17.5m)(27.0m)(44.2m)58.1m128.3m108.8m(29.3m)
USDY, 2019

Revenue/Employee

4.6k

Financial Leverage

1.1 x
Show all financial metrics

Regenxbio Online and Social Media Presence

Embed Graph

Regenxbio News and Updates

Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR

This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…

Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday

Regenxbio Blogs

REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer

REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer Content Import Wed, 04/17/2019 - 07:04 REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer April 17, 2019 at 7:00 AM EDT This release is a backfill from a News Wire General …

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting Content Import Mon, 04/15/2019 - 16:08 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting April 15, 2019 at 4:05 PM …

REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Feb. 27, 2019 /PRNewswire/ -- Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMD Completed dosing of six additional subjects in the fourth cohort for a total of 12 subjects; 30 subjects dosed across four cohorts in the trial On-track to initiate Phase

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights Content Import Wed, 02/20/2019 - 07:06 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial R…

REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease

REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease Content Import Thu, 01/31/2019 - 07:04 REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Dis…

REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. , Jan. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will present at the 37 th
Show more

Regenxbio Frequently Asked Questions

  • When was Regenxbio founded?

    Regenxbio was founded in 2009.

  • Who are Regenxbio key executives?

    Regenxbio's key executives are Ken Mills, Vit Vasista and Stephen Yoo.

  • How many employees does Regenxbio have?

    Regenxbio has 192 employees.

  • What is Regenxbio revenue?

    Latest Regenxbio annual revenue is $218.5 m.

  • What is Regenxbio revenue per employee?

    Latest Regenxbio revenue per employee is $1.1 m.

  • Who are Regenxbio competitors?

    Competitors of Regenxbio include Syros Pharmaceuticals, ZIOPHARM Oncology and Oxford Genetics.

  • Where is Regenxbio headquarters?

    Regenxbio headquarters is located at 9712 Medical Center Dr #100, Rockville.

  • Where are Regenxbio offices?

    Regenxbio has an office in Rockville.

  • How many offices does Regenxbio have?

    Regenxbio has 1 office.